Efficacy and Safety of Apixaban in the Treatment of Heparin Induced Thrombocytopenia (HIT)
This research study is studying a drug as a possible treatment for heparin induced thrombocytopenia (HIT) or Heparin-induced Thrombocytopenia and Thrombosis (HITT).
The drug involved in this study is apixaban.
A Phase II study to evaluate the efficacy and safety of apixaban in the treatment of heparin induced thrombocytopenia (HIT)
- ClinicalTrials.gov Identifier: NCT03594045
- Protocol Number: 18-153
- Principal Investigator: Jeffrey Zwicker
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required